Protalix BioTherapeutics Announces Q2 2025 Results, New CFO to Take Over.

Protalix BioTherapeutics reported Q2 2025 financial and operational results, with revenue growth driven by higher Elfabrio sales and lower Elelyso sales. The company expects to launch the PRX-115 trial in H2 and enroll the first patient by year-end. Protalix will gain a new CFO, Gilad Mamlok, and has been added to the Russell 2000 and 3000 indices. Management provided detail on sales recognition, but did not provide revenue guidance for future quarters.

Protalix BioTherapeutics (PLX) reported robust Q2 2025 financial results, with revenue growth driven primarily by higher sales of Elfabrio® and lower sales of Elelyso®. The company expects to launch the PRX-115 trial in the second half of 2025 and enroll the first patient by the end of the year. Protalix will also welcome a new CFO, Gilad Mamlok, and has been added to the Russell 3000 and 2000 indices.

Revenue from selling goods increased 16% to $15.4 million compared to Q2 2024, driven by an $8 million increase in sales to Chiesi for Elfabrio®. Despite a decrease in sales to Brazil and Pfizer, the company achieved a net income of $164,000, compared to a net loss of $2.2 million in the same period last year. Research and development expenses doubled quarter-over-quarter to $6 million, reflecting increased investment in clinical development, particularly for PRX-115.

Protalix's Q2 2025 results demonstrate a significant transition towards profitability. The company's revenue growth was primarily attributed to an $8 million increase in sales to Chiesi for Elfabrio®, their Fabry disease treatment. This growth was partially offset by a $4.7 million reduction in sales to Fiocruz and a $1.2 million reduction in sales to Pfizer. The management's commentary about quarterly fluctuations in the "early launch phase" signals that Elfabrio's sales trajectory may remain variable in the near term while the product gains market traction.

The company's cash position remains strong, with $33.4 million in cash and cash equivalents at the end of the quarter. Protalix plans to initiate a Phase II trial for PRX-115, their gout treatment candidate, in Q4 2025. The company ended the quarter with $33.4 million in cash and cash equivalents.

Protalix BioTherapeutics' Q2 2025 results highlight the company's progress in commercializing Elfabrio® and advancing its pipeline. The company's strategic focus on internal growth and responsible pipeline development signals confidence in its commercial partnership model and strategic direction moving forward.

References:
[1] https://seekingalpha.com/news/4485575-protalix-signals-100m-elfabrio-royalties-by-2030-as-phase-ii-prxminus-115-trial-advances
[2] https://seekingalpha.com/news/4485229-protalix-biotherapeutics-gaap-eps-of-000-misses-by-003-revenue-of-1566m-beats-by-218m
[3] https://www.stocktitan.net/news/PLX/protalix-bio-therapeutics-reports-second-quarter-2025-financial-and-bz5ngonczfju.html